Monoclonal Antibodies in the Treatment of Malignancy: Basic Concepts and Recent Developments

REFERENCES

• Dillman R. O. Monoclonal Antibodies for Treating Cancer. Ann. Intern. Med. 1989; 11: 592–603
   Google Scholar
• Wright P. W., Hellstrom K. E., Hellstrom I. E., et al. Serotherapy of Malignant Disease. Med. Clin. North Am. 1976; 60: 607–622
   PubMed Web of Science ®Google Scholar
• Ehrlich P. Uben den Jetzigen Stand der Karzinomforschung. The Collected Papers of Paul Ehrlich. Pergamon Press, London 1957; II: 550–557
   Google Scholar
• Kohler H., Milstein C. Continuous Cultures of Fused Cells Secreting Antibody of Predetermined Specificity. Nature 1975; 256: 495–497
   PubMed Web of Science ®Google Scholar
• Dillman R. O. Antibodies as Cytotoxic Therapy. J. Clin. Oncol. 1994; 12: 1497–1515
   PubMed Web of Science ®Google Scholar
• James K. Human Monoclonal Antibodies and Engineered Antibodies in the Management of Cancer. Cancer Biol. 1990; 1: 243–253
   PubMedGoogle Scholar
• Adair J. R. Engineering Antibodies for Therapy. Immunol. Rev. 1992; 130: 5–40
   PubMedGoogle Scholar
• Dillman R. O. Antibody Therapy. Principles of Cancer Biotherapy, R. K. Oldham. 3rd Ed., Kluwer Academic Publishers, The Netherlands 1998; 284–371
   Google Scholar
• Dillman R. O. The Human Antimouse and Antiglobulin Responses to Monoclonal Antibodies. Antibody Immunoconj. Radiopharm 1990; 3: 1–15
   Google Scholar
• Nisonoff A. Idiotypes: Concepts and Applications. Cancer Res. 1991; 147: 2429–2438
   Google Scholar
• Miller R. A., Maloney D. G., Warnke R., et al. Treatment of B-Cell Lymphoma with Monoclonal Anti-idiotype Antibody. N. Engl. J. Med. 1981; 306: 517–522
   Web of Science ®Google Scholar
• Meeker T. C., Lowder J., Maloney D. G., et al. A Clinical Trial of Anti-idiotype Therapy for B Cell Malignancy. Blood 1985; 65: 1349–1372
   PubMed Web of Science ®Google Scholar
• Fan Z., Mendelsohn J. Therapeutic Application of Anti-growth Factor Receptor Antibodies. Curr. Opin. Oncol. 1998; 10: 67–73
   PubMed Web of Science ®Google Scholar
• Herlyn D., Wettendorff M., Schmoll E., et al. Anti-idiotype Immunization of Cancer Patients: Modulation of the Immune Response. Proc. Natl. Acad. Sci. U.S.A. 1987; 84: 8055–8059
   PubMed Web of Science ®Google Scholar
• Mittelman A., Chen Z. J., Yang H., et al. Human High Molecular Weight Melanoma-Associated Antigen (HMW-MAA) Mimicry by Mouse Anti-idiotypic Monoclonal Antibody MK2-23: Induction of Humoral Anti-HMW-MAA Immunity and Prolongation of Survival in Patients with Stage IV Melanoma. Proc. Natl. Acad. Sci. U.S.A. 1992; 89: 466–470
   PubMed Web of Science ®Google Scholar
• Modolfsky P. J., Sears H. F., Mulhearn C. B., jr., et al. Detection of Metastatic Tumor in Normal Sized Retroperitoneal Lymph Nodes by Monoclonal Antibody Imaging. N. Engl. J. Med. 1984; 311: 106–107
   PubMed Web of Science ®Google Scholar
• Surwit E. A., Childers J. M., Krag D. N., et al. Clinical Assessment of 111In-CYT-103 Immunoscintigraphy in Ovarian Cancer. Gyn. Oncol. 1993; 48: 285–292
   PubMed Web of Science ®Google Scholar
• Winzelberg G. G., Grossman S. J., Rizk S., et al. Indium-111 Monoclonal Antibody B72.3 Scintigraphy in Colorectal Cancer: Correlation with Computed Tomography, Surgery, Histopathology, Immunohistology, and Human Immune Response. Cancer 1992; 69: 1656–1663
   PubMed Web of Science ®Google Scholar
• Halpern S. E., Dillman R. O., Amox D., et al. Detection of Occult Tumor Using Indium 111-Labeled Anticarcinoembryonic Antigen Antibodies. Arch. Surg. 1992; 127: 1094–1100
   PubMed Web of Science ®Google Scholar
• Moffat F. L., jr., Pinsky C. M., Hammershalmb L., et al. Clinical Utility of External Immunoscintigraphy with the IMMU-4 Technetium-99-Fab′ Antibody Fragment in Patients Undergoing Surgery for Carcinoma of the Colon and Rectum. Results of a Pivotal, Phase III Trial. J. Clin. Oncol. 1996; 14: 2295–2305
   PubMed Web of Science ®Google Scholar
• Serafini A. N., Klein J. L., Wolff B. G., et al. Radioimmunoscintigraphy of Recurrent, Metastatic, or Occult Colorectal Cancer with Technetium 99-m-Labeled Totally Human Monoclonal Antibody 88BV59: Results of Pivotal, Phase III Multicenter Studies. J. Clin. Oncol. 1998; 16: 1777–1787
   PubMed Web of Science ®Google Scholar
• Meredith R. F., LoBuglio A. F. Recent Progress in Radioimmunotherapy for Cancer. Oncology 1997; 11: 979–987
   PubMedGoogle Scholar
• Wilder R. B., DeNardo G. L., DeNardo S. J. Radioimmunotherapy: Recent Results and Future Directions. J. Clin. Oncol. 1996; 14: 1383–1400
   PubMed Web of Science ®Google Scholar
• Spitler L. E. Immunotoxins. Principles of Cancer Biotherapy, R. K. Oldham. 3rd Ed., Kluwer Academic Publishers, The Netherlands 1998; 318–337
   Google Scholar
• Frankel A. E. Immunotoxin Therapy of Cancer. Oncology 1993; 7: 69–78
   PubMedGoogle Scholar
• Dillman R. O., Johnson D. E., Ogden J. R., et al. Significance of Antigen, Drug and Tumor Cell Targets in the Preclinical Evaluation of Doxorubicin, Daunorubicin, Methotrexate, and Mitomycin-C Monoclonal Antibody Immunoconjugates. Mol. Biother. 1989; 1: 250–255
   PubMedGoogle Scholar
• Oldham R. K., Foon K. Drug Immunoconjugates. Principles of Cancer Biotherapy, R. K. Oldham. 3rd Ed., Kluwer Academic Publishers, The Netherlands 1998; 338–347
   Google Scholar
• Dillman R. O., Dillman J. B., Halpern S. E., et al. Toxicities and Side Effects Associated with Intravenous Infusions of Monoclonal Antibodies. J. Biol. Response Modif. 1986; 5: 73–84
   PubMedGoogle Scholar
• Dillman R. O., Beauregard J. C., Jamieson M., et al. Toxicities Associated with Monoclonal Antibody Infusions in Cancer Patients. Mol. Biother. 1988; 1: 81–85
   PubMedGoogle Scholar
• Winkler U., Jensen M., Manzke O., et al. Severe Side Effects in Patients with B-Cell Chronic Lymphocytic Leukemia and Lymphocytosis Treated with the Monoclonal Anti-CD20 Antibody Rituximab. Blood 1998; 92(10 suppl 1)285b
   Google Scholar
• Byrd J. C., Waselenko J. K., Maneatis T. A., et al. Rituximab Therapy in Hematologic Malignancy Patients with Circulating Blood Tumor Cells: Association with Increased Infusion-Related Side Effects and Rapid Tumor Clearance. J. Clin. Oncol. 1999; 17: 791–795
   PubMed Web of Science ®Google Scholar
• Schneck D., Butler F., Dugan W., et al. Phase I Studies with a Murine Monoclonal Antibody Vinca Conjugate (KS1/4-DAVLB) in Patients with Adenocarcinoma Antibody. Immunoconj. Radiopharm 1989; 2: 93–100
   Google Scholar
• Pai L. H., Bookman M. A., Ozols R. F., et al. Clinical Evaluation of Intraperitoneal Pseudomonas Exotoxin Immunoconjugate OBV3-PE in Patients with Ovarian Cancer. J. Clin. Oncol. 1991; 9: 2095–2103
   PubMed Web of Science ®Google Scholar
• Nadler L. M., Stashenko P., Hardy R., et al. Serotherapy of a Patient with a Monoclonal Antibody Directed Against a Human Lymphoma-Associated Antigen. Cancer Res. 1980; 40: 3147–3154
   PubMed Web of Science ®Google Scholar
• Ball E. D., Bernier G. M., Cornwell G. G., III, et al. Monoclonal Antibodies to Myeloid Differentiation Antigens: In Vivo Studies of Three Patients with Acute Myelogenous Leukemia. Blood 1983; 62: 1203–1210
   PubMed Web of Science ®Google Scholar
• Ritz J., Pesando J. M., Sallan S. E., et al. Serotherapy of Acute Lymphoblastic Leukemia with Monoclonal Antibody. Blood 1981; 58: 141–152
   PubMed Web of Science ®Google Scholar
• Miller R. A., Oseroff A. R., Stratte P. T., et al. Monoclonal Antibody Therapeutic Trials in Seven Patients with T-Cell Lymphoma. Blood 1983; 62: 988–995
   PubMed Web of Science ®Google Scholar
• Dillman R. O., Shawler D. L., Dillman J. B., et al. Therapy of Chronic Lymphocytic Leukemia and Cutaneous T-Cell Lymphoma with T101 Monoclonal Antibody. J. Clin. Oncol. 1984; 2: 881–891
   PubMed Web of Science ®Google Scholar
• Dillman R. O., Shawler D. L., Sobol R. E., et al. Murine Monoclonal Antibody Therapy in Two Patients with Chronic Lymphocytic Leukemia. Blood 1982; 59: 1036–1045
   PubMed Web of Science ®Google Scholar
• Foon K. A., Schroff R. W., Bunn P. A., et al. Effects of Monoclonal Antibody Therapy in Patients with Chronic Lymphocytic Leukemia. Blood 1984; 64: 1085–1093
   PubMed Web of Science ®Google Scholar
• Press O. W., Appelbaum F., Ledbetter J. A., et al. Monoclonal Antibody 1F5 (Anti-CD-20) Serotherapy of Human B Cell Lymphomas. Blood 1987; 69: 584–591
   PubMed Web of Science ®Google Scholar
• Goodman G. E., Beaumier P., Hellstrom I., et al. Pilot Trial of Murine Monoclonal Antibodies in Patients with Advanced Melanoma. J. Clin. Oncol. 1985; 3: 340–352
   PubMed Web of Science ®Google Scholar
• Houghton A. N., Mintzer D., Cordon-Cardo C., et al. Mouse Monoclonal IgG3 Antibody Detecting GD3 Ganglioside: A Phase I Trial in Patients with Malignant Melanoma. Proc. Natl. Acad. Sci. U.S.A. 1985; 82: 1242–1246
   PubMed Web of Science ®Google Scholar
• Sears H. F., Herlyn D., Steplewski Z., et al. Phase II Clinical Trial of a Murine Monoclonal Antibody Cytotoxic for Gastrointestinal Adenocarcinoma. Cancer Res. 1985; 45: 5910–5913
   PubMed Web of Science ®Google Scholar
• Mellstedt H., Frodin J-E., Masucci G., et al. The Therapeutic Use of Monoclonal Antibodies in Colorectal Carcinoma. Semin. Oncol. 1991; 18: 462–477
   PubMed Web of Science ®Google Scholar
• Dillman R. O., Shawler D. L., McCallister T. J., et al. Human Anti-mouse Antibody Response in Cancer Patients Following Single Low-Dose Injections of Radiolabeled Murine Monoclonal Antibodies. Cancer Biother. 1994; 9: 17–28
   PubMedGoogle Scholar
• Khazaeli M. B., Conry R. M., LoBuglio A. F. Human Immune Response to Monoclonal Antibodies. J. Immunother. 1994; 15: 42–52
   PubMed Web of Science ®Google Scholar
• Oldham R. K., Foon K. A., Morgan C., et al. Monoclonal Antibody Therapy of Malignant Melanoma: In Vivo Localization in Cutaneous Metastases After Intravenous Administration. J. Clin. Oncol. 1984; 2: 11235–11244
   Google Scholar
• Caufield M. J., Barna B., Murthy S., et al. Phase Ia/Ib Trial of an Anti-GD3 Monoclonal Antibody (R24) in Combination with Interferon Alpha (rHuIFNα-2a) in Patients with Malignant Melanoma. J. Biol. Response Modif. 1990; 9: 319–328
   PubMedGoogle Scholar
• Saleh M. N., LoBuglio A. F., Wheeler R. H., et al. A Phase II Trial of Murine Monoclonal Antibody 17-1A and Interferon Gamma: Clinical and Immunological Data. Cancer Immunol. 1990; 32: 185–190
   Google Scholar
• Chachoua A., Oratz R., Liebes L., et al. Phase Ib Trial of Granulocyte-Macrophage Colony-Stimulating Factor Combined with Murine Monoclonal Antibody R24 in Patients with Metastatic Melanoma. J. Immunother. 1994; 16: 132–141
   PubMed Web of Science ®Google Scholar
• Dillman R. O. Whither Magic Bullets and Guided Missiles: Monoclonal Antibodies 20 Years Later. Cancer Biother. 1995; 10: 177–180
   PubMedGoogle Scholar
• Dillman R. O. Magic Bullets at Last! Finally—Approval of a Monoclonal Antibody for the Treatment of Cancer!!!. Cancer Biother. 1997; 12: 223–225
   Google Scholar
• McLaughlin P., Grillo-Lopez A. J., Link B. K., et al. Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program. J. Clin. Oncol. 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Coiffier B., Haioun C., Ketterer N., et al. Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients with Relapsing or Refractory Aggressive Lym-phoma: A Multicenter Phase II Study. Blood 1998; 92: 1927–1932
   PubMed Web of Science ®Google Scholar
• Baselga J., Tripathy D., Mendelsohn J., et al. Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients with HER2/neu Overexpressing Metastatic Breast Cancer. J. Clin. Oncol. 1996; 14: 737–744
   PubMed Web of Science ®Google Scholar
• Pegram M. D., Lipton A., Hayes D. F., et al. Phase II Study of Receptor-Enhanced Chemosensitivity Using Recombinant Humanized Anti-p185HER2/neu Monoclonal Antibody Plus Cisplatin in Patients with HER2/neu Overexpressing Metastatic Breast Cancer Refractory to Chemotherapy Treatment. J. Clin. Oncol. 1998; 16: 2659–2671
   PubMed Web of Science ®Google Scholar
• Dillman R. O. Perceptions of Herceptin®: A Monoclonal Antibody for the Treatment of Breast Cancer. Cancer Biother. 1999; 14: 5–10
   Google Scholar
• Waldmann T. A., Goldman C. K., Bongiovanni K. F., et al. Therapy of Patients with Human T-Cell Lymphotropic Virus I-Induced Adult T-Cell Leukemia with Anti-tac, a Monoclonal Antibody to the Receptor for Interleukin-2. Blood 1988; 72: 1805–1816
   PubMed Web of Science ®Google Scholar
• LeMaistre C. F., Saleh M. N., Kuzel T. M., et al. Phase I Trial of a Ligand Fusion-Protein (DAB389IL-2) in Lymphomas Expressing the Receptor for Interleukin-2. Blood 1998; 91: 399–405
   PubMed Web of Science ®Google Scholar
• Saleh M. N., LeMaistre C. F., Kuzel T. M., et al. Antitumor Activity of DAB389IL-2 Fusion Toxin in Mycosis Fungoides. J. Am. Acad. Dermatol. 1998; 39: 63–73
   PubMed Web of Science ®Google Scholar
• Riethmuller G., Holz E., Schlimok G., et al. Monoclonal Antibody Therapy for Resected Dukes' C Colorectal Cancer: Seven-Year Outcome of a Multicenter Randomized Trial. J. Clin. Oncol. 1998; 16: 1788–1794
   PubMed Web of Science ®Google Scholar
• Hale G., Dyer M., Clark M. R., et al. Remission Induction in Non-Hodgkin's Lymphoma with Reshaped Human Monoclonal Antibody CAMPATH-1H. Lancet 1988; 2: 1394–1399
   PubMed Web of Science ®Google Scholar
• Osterborg A., Dyer M. J.S., Bunjes D., et al. Phase II Multicenter Study of Human CD52 Antibody in Previously Untreated Chronic Lymphocytic Leukemia. J. Clin. Oncol. 1997; 15: 1567–1574
   PubMed Web of Science ®Google Scholar
• Lundin J., Osterborg A., Brittinger G., et al. CAMPATH1-H Monoclonal Antibody in Therapy for Previously Treated Low-Grade Non-Hodgkin's Lymphomas: A Phase II Multicenter Study. J. Clin. Oncol. 1998; 16: 3257–3263
   PubMed Web of Science ®Google Scholar
• Keating M. J., Byrd J., Rai K., et al. Multicenter Study of Campath-1H in Patients with Chronic Lymphocytic Leukemia (B-CLL) Refractory to Fludarabine. Blood 1999; 94(10 suppl 1)705a, (abstract)
   Google Scholar
• Sievers E. L., Larson R. A., Stadtmauer E. A., et al. Efficacy and Safety of Gemtuzumab Ozogamicin in Patients with CD33-Positive Acute Myeloid Leukemia in First Relapse. J. Clin. Oncol. 2001; 19: 3244–3254
   PubMed Web of Science ®Google Scholar
• Kaminski M. S., Zasadny K. R., Francis I. R., et al. Radioimmunotherapy of B-Cell Lymphoma with 131I-Anti-B1 (Anti-CD20) Antibody. N. Engl. J. Med. 1993; 329: 459–465
   PubMed Web of Science ®Google Scholar
• Kaminski M. S., Azsadny K. R., Francis I. R., et al. Iodine-131-Anti-B1 Radioimmunotherapy for B-Cell Lymphoma. J. Clin. Oncol. 1996; 14: 1974–1981
   PubMed Web of Science ®Google Scholar
• Vose J. M., Wahl R. L., Saleh M., et al. Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas. J. Clin. Oncol. 2000; 18: 1316–1323
   PubMed Web of Science ®Google Scholar
• Knox S. J., Goris M. L., Trisler K., et al. Yttrium-90-Labeled Anti-CD20 Monoclonal Antibody Therapy of Recurrent B-Cell Lymphoma. Clin. Cancer Res. 1996; 2: 457–470
   PubMed Web of Science ®Google Scholar
• Gordon L. I., White C. A., Witzig T. E., et al. Zevalin™ (IDEC-Y2B8) Radioimmunotherapy of Rituximab Refractory Follicular Non-Hodgkin's Lymphoma: Interim Results. Blood 1999; 94(10 suppl 1)91a, (abstract)
   Google Scholar
• Caron P. C., Jurcic J. G., Scott A. M., et al. A Phase 1B Trial of Humanized Monoclonal Antiboyd M195 (Anti-CD33) in Myeloid Leukemia: Specific Targeting Without Immunogenicity. Blood 1994; 83: 1760–1768
   PubMed Web of Science ®Google Scholar
• Jurcic J. G., Caron P. C., Nikula T. K., et al. Radiolabeled Anti-CD33 Monoclonal Antibody M195 for Myeloid Leukemias. Cancer Res. 1995; 55(3 suppl)5908s–5910s
   Google Scholar
• Oldham R. K. Biologicals and Biological Response Modifiers: The Fourth Modality of Cancer Treatment. Cancer Treat. Rep. 1984; 68: 221–232
   PubMedGoogle Scholar